

## **BARD1 SIGNS AGREEMENT WITH GRIFFITH UNIVERSITY**

- **BARD1 signs Consultancy and Commercial Research Agreement with the Mucosal Immunology Research Group (MIRG) at Griffith University**
- **MIRG has key expertise in the development and validation of diagnostic assays for infectious and inflammatory responses**
- **Agreement provides the Company with Australian-based diagnostics development expertise and research capacity in readiness for transfer of its development activities to Australia**

**Perth, Australia, 2 April 2020:** BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**), a medical technology company developing non-invasive cancer diagnostics, is pleased to announce it has signed a commercial research agreement with Griffith University.

BARD1 has signed a Consultancy and Commercial Research Agreement with Griffith University to provide consultancy and scientific services to support the development and commercialization of the BARD1 technology for detection of ovarian, breast and lung cancer. The Agreement will be delivered through the experienced team at the Mucosal Immunology Research Group (MIRG) at Griffith University that has significant expertise in immunoassay development for the detection of infection and quantitation of inflammatory/immune responses.

BARD1 CEO, Dr Leearne Hinch, said: "This Agreement with Griffith University further delivers on our growth strategy to build additional local expertise and research capacity in readiness for our relocation to the east coast and transfer of our development activities to Australia. Importantly, it provides the Company with local access to additional expertise in immunoassay development and performance, biostatistical analysis and critical biospecimens for future clinical validation studies as we advance our diagnostic programs towards commercialisation."

- ENDS -

### **COMPANY CONTACTS:**

**Dr Leearne Hinch**  
CEO

**E** [leearne@bard1.com](mailto:leearne@bard1.com)

**M** +61 400 414 416

**Peter Gunzburg**  
Chairman

**E** [peter@bard1.com](mailto:peter@bard1.com)

### **ABOUT BARD1 LIFE SCIENCES LTD**

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian medical technology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1 owns a proprietary tumour marker platform with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes BARD1 autoantibody tests in development for early detection of ovarian, breast and lung cancers. BARD1's mission is to detect cancer earlier and save lives. For more information on BARD1, see [www.bard1.com](http://www.bard1.com).

### **ABOUT GRIFFITH UNIVERSITY**

The Mucosal Immunology Research Group within the Menzies Health Institute QLD at Griffith University is focused on understanding the role of the immune system in human health and disease. This focus is achieved through a range of pre-clinical and clinical collaborative research initiatives with clinicians and commercial partners. The MIRG has expertise in laboratory and diagnostic assays and data science to better understand the role of the immune system in human health and disease.

At Griffith, we believe in, strive for and celebrate the Remarkable. The remarkable people who better our world, the remarkable experiences that transform people and communities, and the remarkable contributions that change the future forever. Our teaching and research spans six campuses in South East Queensland and all disciplines, while our network of more than 200,000 graduates extends around the world.

Griffith University ranks among the world's best universities and continues to improve its international standing. In the largest world university rankings, Griffith is rated in the top 2%. Young and ambitious, Griffith is also ranked in the top 50 universities under 50 years of age

#### **FORWARD LOOKING STATEMENTS**

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.